Investor Newsletter

Issue 02 2023

MicroPort®



First Implantation of Endovastec™'s Castor™ Branched Aortic Stent-Graft System Completed in Netherlands

The first implantation of the Castor® Aortic Branched Stent-Graft and Delivery System (Castor®) developed by Endovastec™ has been successfully completed in Netherlands. This marks the product's 11th global market debut, following the United Kingdom, Poland, Spain, Argentina and others. The procedure was performed by a team led by Professor Kak Khee Yeung of Amsterdam University Hospital.

The Castor® was launched in 2017 and entered global markets in 2020 and has since been recognized by experts for its excellent performance in clinical applications in China, Europe and South America, with over 13,000 aortic disease patients having been treated worldwide. The first implanation of the Castor® in the Netherlands is a significant step for Endovastec™'s growth in the European market.

VitaFlow Liberty™ and Alwide® Plus by CardioFlow Medtech Obtain Marketing Approval in Thailand

CardioFlow Medtech has recently obtained registration approval from the Food and Drug Administration, Thailand for its independently developed transcatheter aortic valve implantation (TAVI) solutions, the VitaFlow Liberty™ Transcatheter Aortic Valve and Retrievable Delivery System (VitaFlow Liberty™) together with the Alwide® Plus Balloon Catheter (Alwide® Plus).

Prior to the successful launch of VitaFlow Liberty™ and Alwide® Plus in Thailand, VitaFlow® and Alwide® had already received marketing approval. Currently, CardioFlow Medtech's products have entered Colombia, Argentina, Brazil, and Thailand. In the future, CardioFlow Medtech will continue to accelerate the commercialization of innovative products with international competitiveness, introducing TAVI products to more countries and regions with the aim to bring high-quality, universal total solutions for structural heart disease to more patients and physicians worldwide.

MicroPort

MicroPort EP Obtains FDA Approval for EasyFinder™ Fixed Curve Diagnostic Catheter

Recently, MicroPort EP obtained approval from the Food and Drug Administration in the United States of America (U.S.) for its independently researched and developed EasyFinder™ Fixed Curve Diagnostic Catheter. This product is the first mapping catheter from MicroPort EP to get FDA approval.

The EasyFinder™ Fixed Curve Diagnostic Catheter has been certified by the FDA and entered into the U.S. market for sale, further promoting the internationalization process of the company's products, bringing positive impact on their promotion in global markets, and enhancing brand awareness, globally.

In the future, MicroPort EP will continue to invest in technological research and development, as well as product innovation, so as to provide more high-quality products and professional services, offering comprehensive EP diagnostic and therapeutic solutions for doctors and patients worldwide.

MicroPort

ArgusClarity™ OCT System by MicroPort Argus™ Registered for Marketing in Singapore

MicroPort Argus™ has recently received registration approval from the Singaporean Health Sciences Authority for its independently developed intravascular optical coherence tomography (OCT) endoluminal imaging device, the ArgusClarity™ OCT imaging system.

This marketing approval marks an additional global approval for the ArgusClarity™ OCT imaging system, following its CE marketing certification. In the future, MicroPort® will continue to relentlessly pursue innovation, take the initiative to expand into global markets, as well as to provide high-quality and comprehensive medical solutions for patients and physians worldwide.

MicroPort

Investor Newsletter

MicroPort®

For more information, please contact:

Martin Sun
Chief Financial Officer
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com

Leanne Li
Board Secretary & VP of Securities Affairs
MicroPort Scientific Corporation
Tel: (86)(21) 38954600
Email: ir@microport.com